LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akcijų sąrašas・Compugen Ltd

Compugen Ltd

Uždarymo kaina

2.8 7.28

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.67

Max

2.91

Pagrindiniai rodikliai
By Trading Economics
Pajamos	64M 57M
Pardavimai	65M 67M
P/E Sektoriaus vid.	7.526 49.701
Pelno marža	84.425
Darbuotojai	75
EBITDA	63M 56M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+69.64% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	59M 270M
Ankstesnė atidarymo kaina	-4.48
Ankstesnė uždarymo kaina	2.8

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-22 16:33; UTC

Uždarbis

Pagrindinės rinkos jėgos

Webull Shares Slide on 1Q Loss, Soaring Costs

2026-05-22 21:10; UTC

Uždarbis

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026-05-22 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 19:47; UTC

Uždarbis

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026-05-22 19:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026-05-22 19:10; UTC

Rinkos pokalbiai

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026-05-22 18:38; UTC

Rinkos pokalbiai

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026-05-22 18:35; UTC

Įsigijimai, susijungimai, perėmimai

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026-05-22 18:09; UTC

Rinkos pokalbiai

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026-05-22 17:58; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

2026-05-22 17:54; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2026-05-22 17:54; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-22 17:54; UTC

Rinkos pokalbiai

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

2026-05-22 17:03; UTC

Rinkos pokalbiai

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

2026-05-22 16:54; UTC

Rinkos pokalbiai

Crypto Spot Volumes Fall 14% in April -- Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 16:16; UTC

Rinkos pokalbiai

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

2026-05-22 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-22 15:55; UTC

Rinkos pokalbiai

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

2026-05-22 15:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-22 15:42; UTC

Rinkos pokalbiai

Oil Continues as Leading Indicator for All Markets -- Market Talk

2026-05-22 15:35; UTC

Rinkos pokalbiai

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

69.64% į viršų

12 mėnesių prognozė

Vidutinis 4.75 USD 69.64%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.